CoChat

Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension

The DOI matches its Crossref record; 33 of the 35 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To investigate the efficacy, safety, and tolerability of empagliflozin in patients with type 2 diabetes and hypertension. RESEARCH DESIGN AND METHODS: Patients (N = 825) with type 2 diabetes and hypertension (mean seated systolic blood pressure [SBP] 130–159 mmHg and diastolic blood pressure [DBP] 80–99 mmHg) were randomized (double blind) to 10 mg or 25 mg empagliflozin or placebo once daily for 12 weeks. RESULTS: At week 12, adjusted mean difference versus placebo in change from baseline in mean 24-h SBP (ambulatory blood pressure monitoring [ABPM]) was −3.44 mmHg (95% CI −4.78, −2.09) with 10 mg empagliflozin and −4.16 mmHg (−5.50, −2.83) with 25 mg empagliflozin (both P < 0.001). At week 12, adjusted mean difference versus placebo in change from baseline in mean 24-h DBP (ABPM) was −1.36 mmHg (95% CI −2.15, −0.56) with 10 mg empagliflozin and −1.72 mmHg (95% CI −2.51, −0.93) with 25 mg empagliflozin (both P < 0.001). Changes in office BP were consistent with ABPM. Adjusted mean difference versus placebo in change from baseline in HbA1c at week 12 was −0.62% (95% CI −0.72, −0.52) (−6.8 mmol/mol [95% CI −7.9, −5.7]) with 10 mg empagliflozin and −0.65% (95% CI −0.75, −0.55) (−7.1 mmol/mol [95% CI −8.2, −6.0]) with 25 mg empagliflozin (both P < 0.001). Empagliflozin was well tolerated. One patient on placebo and one patient on 10 mg empagliflozin reported events consistent with volume depletion. CONCLUSIONS: Empagliflozin was associated with significant and clinically meaningful reductions in BP and HbA1c versus placebo and was well tolerated in patients with type 2 diabetes and hypertension.

Overview

Integrity signals

Registry

Crossref · 10.2337/dc14-1096

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

See all 505

Metadata

Authors
Tikkanen, I., Narko, K., Zeller, C., Green, A., Salsali, A., Broedl, U. C., & Woerle, H. J.
Affiliations
  • Helsinki University Hospital (FI)
  • Boehringer Ingelheim (Finland) (FI)
  • Boehringer Ingelheim (Germany) (DE)
  • inVentiv Health Clinical (CA)
Corresponding author
Tikkanen, Ilkka
Venue
Diabetes Care
Published
2014-09-30
Volume
38
Issue
3
Pages
420-428
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2138173919
Cited by
468
References
35
Citations by year
2026: 19 · 2025: 29 · 2024: 27 · 2023: 41 · 2022: 39 · 2021: 38 · 2020: 41 · 2019: 50 · 2018: 44 · 2017: 52 · 2016: 53 · 2015: 31 · 2014: 3
FWCI
31.78
Type
journal article
Language
en
Open access
closed
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Eli Lilly and Company
  • Boehringer Ingelheim
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords
empagliflozin, type 2 diabetes, hypertension, blood pressure reduction, SGLT2 inhibitors, ambulatory blood pressure monitoring, glycemic control, HbA1c, tolerability, adverse events, dose comparison, antihypertensive therapy, renin-angiotensin system blockade
MeSH terms
Analysis of Variance, Antihypertensive Agents, Benzhydryl Compounds, Blood Pressure, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Double-Blind Method, Drug Administration Schedule, Female, Glucosides, Glycated Hemoglobin, Humans, Hypertension, Hypoglycemic Agents, Male, Middle Aged, Weight Loss, Treatment Outcome, Blood Pressure Monitoring, Ambulatory

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.